To minimize this bias, we conducted a second multivariate analysis model on 134 pairs of patients excluding pairs with family history of VTE, and we confirmed a six-fold increase of cancer-associated thrombosis risk due to FVL mutation (adjusted OR, 6.27 [1.39–28.23], p = 0.017). The gene discussed is F5; the disease is Venous thrombosis.